Skizofrenia Paranoid dengan Gangguan Insight dan Kepatuhan Terapi: Sebuah Laporan Kasus
DOI:
https://doi.org/10.71417/galen.v2i1.165Keywords:
Antipsikotik, Halusinasi, Insight, Skizofrenia Paranoid, Kepatuhan TerapiAbstract
Skizofrenia paranoid yang ditandai gejala positif dominan seperti halusinasi auditorik dan waham kejar menimbulkan tantangan signifikan pada dewasa muda akibat gangguan insight dan ketidakpatuhan terapi, terutama di Indonesia dengan prevalensi 1,7 per 1000 dan kepatuhan rendah 50%. Mendokumentasikan perjalanan klinis, diagnosis, dan tatalaksana skizofrenia paranoid dengan gangguan insight. Studi kasus observasional deskriptif kualitatif di RS Muhammadiyah Lamongan menggunakan auto/heteroanamnesis, pemeriksaan status mental, skala GAF; analisis tematik dengan triangulasi DSM-5-TR/PPDGJ-III. Sampel purposive tunggal AS (laki-laki, 21 tahun, onset 2024). Pasien mengalami bisikan auditorik, bayangan visual sejak 2024, perubahan perilaku, penolakan pengobatan menyebabkan kekambuhan 2025; diagnosis F20.0, capai GAF 81-90 pasca-terapi aripiprazole 5 mg BID plus trihexyphenidyl. Kombinasi farmakoterapi, psikoedukasi, sleep hygiene, dan dukungan keluarga berhasil mengontrol gejala serta fungsi optimal, menegaskan pentingnya intervensi biopsikososial komprehensif untuk pencegahan kekambuhan di pelayanan prime.
Downloads
References
American Psychiatric Association. (2022). DSM-5-TR: Diagnostic and statistical manual of mental disorders (5th ed., text rev.). Author. https://doi.org/10.1176/appi.books.9780890425787
Arango, C., Dragioti, E., Solmi, F., Cortese, S., Domschke, K., Murray, R. M., ... Correll, C. U. (2021). Risk and protective factors for mental disorders beyond genetics: An evidence-based atlas. World Psychiatry, 20(3), 417–436. https://doi.org/10.1002/wps.20889
Correll, C. U., Solmi, F., Croatto, G., Schneider-Thoma, G., Almasi, A., Bitter, I., ... Leucht, S. (2022). Mortality in people with schizophrenia: A systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry, 21(2), 248–271. https://doi.org/10.1002/wps.20931
Creswell, J. W., & Poth, C. N. (2021). Qualitative inquiry and research design: Choosing among five approaches (5th ed.). SAGE Publications.
Emzir. (2021). Metodologi penelitian kualitatif: Analisis data kualitatif. Pustaka Setia.
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., ... Tran, N. (2021). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian & New Zealand Journal of Psychiatry, 55(5), 429–476. https://doi.org/10.1177/0004867421996501
Higashi, K., Medic, G., Littlewood, K. J., Diez, T., Granström, O., & De Hert, M. (2020). Medication adherence in schizophrenia: Factors influencing adherence and consequences of nonadherence. Patient Preference and Adherence, 14, 117–128. https://doi.org/10.2147/PPA.S192742
Howes, O. D., McCutcheon, R., Owen, M. J., & Murray, R. M. (2020). The role of genes, stress, and dopamine in the development of schizophrenia. Biological Psychiatry, 87(9), 708–715. https://doi.org/10.1016/j.biopsych.2019.09.014
Howes, O. D., & Murray, R. M. (2021). Schizophrenia: An integrated sociodevelopmental-cognitive model. The Lancet, 397(10272), 617–631. https://doi.org/10.1016/S0140-6736(20)32060-0
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., ... Insel, T. R. (2020). Schizophrenia. Nature Reviews Disease Primers, 6(1), Article 1. https://doi.org/10.1038/s41572-020-00205-0
Kishi, T., Matsuda, Y., Iwata, N., & Correll, C. U. (2021). Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: A systematic review and dose-response meta-analysis. Schizophrenia Bulletin, 47(2), 386–399. https://doi.org/10.1093/schbul/sbaa092
Leucht, S., Chaimani, A., Leucht, C., Huhn, M., Mavridis, D., Helfer, B., ... Davis, J. M. (2021). 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. American Journal of Psychiatry, 178(4), 299–308. https://doi.org/10.1176/appi.ajp.2020.20070902
Lincoln, T. M., Lüllmann, E., & Rief, W. (2020). Correlates and long-term consequences of poor insight in patients with schizophrenia: A systematic review. Schizophrenia Bulletin, 46(1), 1–12. https://doi.org/10.1093/schbul/sbz011
McCutcheon, R. A., Abi-Dargham, A., & Howes, O. D. (2023). Schizophrenia, dopamine and the striatum: Evidence and arguments for striatal dysfunction as a new endophenotype in schizophrenia. World Psychiatry, 22(1), 15–29. https://doi.org/10.1002/wps.21062
Solmi, F., Radua, J., Olivola, M., Croce, E., Soardo, L., de Pablo, G. S., ... Fusar-Poli, P. (2022). Age at onset of mental disorders worldwide: Large-scale meta-analysis of 192 epidemiological studies. Molecular Psychiatry, 27(1), 281–295. https://doi.org/10.1038/s41380-021-01161-7
Sugiyono. (2023). Metode penelitian kuantitatif, kualitatif, dan R&D (Edisi ke-28). Alfabeta.
Sudaryono. (2022). Metode penelitian ilmiah pendidikan (Edisi ke-3). Graha Ilmu.
Tandon, R., Gaebel, W., Barch, D. M., Bustillo, J., Gur, R. E., Heckers, S., ... Carpenter, W. (2020). Definition and description of schizophrenia in the DSM-5. Schizophrenia Research, 216, 3–10. https://doi.org/10.1016/j.schres.2019.11.025
van Os, J., Guloksuz, S., Vijn, T. W., Hafkenscheid, A., & Delespaul, P. (2020). The evidence-based group-level symptom-reduction model as the organizing principle for mental health care: Time for change? World Psychiatry, 19(3), 313–320. https://doi.org/10.1002/wps.20793
World Health Organization. (2022). ICD-11: International classification of diseases for mortality and morbidity statistics. https://icd.who.int/
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Shelly Oktifani Rahmasita, Era Catur Prasetya (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
